Core Insights - VivoSim Labs, Inc. has validated its NAMkind™ liver and intestine models for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs) [1][2] Group 1: ADC Toxicity and Validation - The NAMkind™ models are positioned as essential tools to differentiate anticancer activity from unwanted cytotoxicity in ADCs, which are widely used in oncology [2] - Testing of approved ADC therapies in NAMkind™ models shows a strong correlation with clinical results, effectively identifying liver toxicity in drugs like gemtuzumab ozogomicin and low liver toxicity in enfortumab vedotin [3] - The NAMkind™ intestine models can detect differential effects on epithelial cells, providing insights into the overall impact of ADCs on intestinal health [4] Group 2: Industry Impact and Adoption - The models are expected to enhance the success rate of ADC candidates in clinical settings by allowing partners to screen out toxicities during early development stages [5] - VivoSim's NAMkind models are recognized as cutting-edge in the field, with services now available in the US, Europe, Korea, and China, indicating a scaling capacity to meet global demand [6] - The anticipated shift towards non-animal testing methods following FDA announcements is expected to accelerate the adoption of human tissue models in drug development [7]

Core Insights - American Rare Earths has engaged a US-based exploration and geoscience consultancy to conduct a comprehensive review of historical data and design a targeted follow-up work program focused on gold, silver, copper, and other non-rare earth critical minerals at its La Paz Project in Arizona [1][8] Group 1: Project Overview - The La Paz Project encompasses approximately 2,779 hectares (6,866 acres) of unpatented federal lode claims and an additional 260 hectares (640 acres) of state mineral lease, situated in a historically active mining jurisdiction [2] - The company aims to reassess the multi-commodity potential of the La Paz property, moving beyond the previous focus on rare earth elements [2] Group 2: Data Review and Methodology - The consultancy will lead a multi-phase technical review of historical data related to gold, silver, copper, and manganese, including geological mapping and reinterpretation of structures and alteration patterns [3] - Historical drill core and chip samples will be reviewed to identify untested or under-recognized zones of mineralization [4] - Historical geochemical datasets will be compiled and re-evaluated, focusing on pathfinders and anomalies associated with the targeted minerals [4] - An assessment of historic geophysical surveys will be conducted to identify structures that could host metallic mineralization [5] Group 3: Future Exploration Plans - Based on the data review, American Rare Earths may implement a focused exploration program in 2026 to test the most promising precious and base metal opportunities [6] - The exploration strategy will include detailed geological mapping, ground-based geochemical surveys, and selective ground geophysics to validate historical anomalies [7] - The company plans to integrate these work programs with ongoing rare earth element activities to leverage existing infrastructure and geological knowledge [7] Group 4: Strategic Vision - The CEO of American Rare Earths emphasized the potential to unlock additional value from the La Paz Project by adopting a multi-commodity approach to exploration [8] - The company aims to identify new targets for gold, silver, copper, and manganese, which would enhance its broader growth strategy in the US [8]

Core Viewpoint - Hyperion DeFi has entered a partnership with Silhouette to provide staked HYPE for reduced transaction fees on the Hyperliquid platform, indicating growing demand for Hyperliquid and potential revenue scaling opportunities for the company [1][3][4]. Group 1: Partnership and Benefits - The HYPE Asset Use Service (HAUS) agreement allows Silhouette's users to access significantly lower transaction fees when trading on Hyperliquid [2][3]. - Silhouette's architecture ensures that sophisticated trading strategies remain private while providing cost efficiency, allowing all users to trade at the lowest available fee tier [3][4]. - The partnership aims to onboard more market participants into the Hyperliquid ecosystem, enhancing trading activity and revenue generation [3][4]. Group 2: Hyperliquid Platform Overview - Hyperliquid is a next-generation layer one blockchain designed for high-frequency trading, featuring on-chain perpetual futures and spot order books with 70 millisecond block times [5]. - The platform supports a general-purpose smart contract environment through HyperEVM, enabling decentralized financial applications similar to Ethereum [5]. Group 3: HYPE Token Utility - HYPE is the native token of Hyperliquid, providing users with reduced trading fees and increased referral bonuses when staked [6]. - As of March 2026, over 41 million HYPE tokens have been autonomously purchased and sequestered by the blockchain, generating trading fees on the network's central limit order books [6]. Group 4: Company Background - Hyperion DeFi, Inc. is the first publicly listed DeFi company in the U.S. focused on the Hyperliquid ecosystem, offering investors streamlined access to one of the fastest-growing blockchains [7]. - Shareholders benefit from exposure to HYPE through staking yields and additional revenues generated from its on-chain utility [7].

Core Insights - Rocket Doctor AI Inc. has expanded its in-network access by partnering with a major California-based health plan, providing services to an additional 330,000 Medicare Advantage members and over 1.7 million commercially insured members [1][8] Group 1: Strategic Expansion - The agreement enhances Rocket Doctor's strategic growth in California, integrating its digital health platform with leading payer networks [2] - This expansion aims to improve member access to timely, high-quality care and supports efficient healthcare delivery across diverse patient populations [2][5] Group 2: Service Offerings - Physicians in Rocket Doctor's multi-specialty practice will offer a range of services through the digital health platform, including primary care consultations, chronic condition management, virtual urgent care, and preventive health services [4][8] - The platform connects patients with board-certified physicians and utilizes integrated care management tools to address both immediate and ongoing healthcare needs [4] Group 3: Market Position - The latest agreement reinforces Rocket Doctor's position as a trusted partner to payers and providers, advancing its mission to enhance access, affordability, and equity in healthcare [5] - The company has previously announced similar expansions, indicating ongoing momentum in both government-sponsored and commercial insurance markets [3][8]

Core Viewpoint - VenHub Global, Inc. has partnered with Circa Resort & Casino to introduce a unique autonomous Smart Store, marking a significant advancement in the integration of hospitality and technology in retail [1][2]. Group 1: Partnership and Installation - The new autonomous Smart Store will be located at Circa Resort, measuring 66 feet x 10 feet x 10 feet, and is set to debut in Spring 2026 [1]. - This installation will consist of three integrated VenHub Smart Stores, creating a continuous retail experience for guests [2]. Group 2: Retail Experience - The Smart Store will allow guests to autonomously browse and purchase a variety of products, including food, snacks, alcohol, and smokeless tobacco, without wait times or checkout lines [3]. - It is designed to operate 24/7, making it the most accessible retail offering in Las Vegas [3]. Group 3: Technology and Operations - All transactions will be fully autonomous, utilizing VenHub's proprietary robotics and AI platform, ensuring a seamless shopping experience [4][5]. - The Smart Stores will feature mobile-based checkout and real-time inventory tracking, providing secure and convenient access to a wide range of products [5][6]. Group 4: Company Background - VenHub specializes in designing and building autonomous Smart Stores that operate without on-site staff, headquartered in Las Vegas, Nevada [6]. - Circa Resort & Casino is an adults-only casino-resort that combines vintage design with high-tech advancements, featuring various amenities and attractions [6][7].

Core Viewpoint - INmune Bio Inc. will host a conference call on March 30, 2026, to discuss its financial results for the year ended December 31, 2025, and provide a corporate update [1]. Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases [3]. - The company has three product platforms: 1. CORDStrom™, a proprietary platform using human umbilical cord-derived mesenchymal stromal/stem cells, which recently completed a trial for recessive dystrophic epidermolysis bullosa 2. XPro™, designed to selectively neutralize soluble TNF, a key driver of inflammation 3. INKmune®, a cell-based medicine aimed at priming natural killer cells to eliminate minimal residual disease in cancer patients [3]. Conference Call Information - The conference call is scheduled for March 30, 2026, at 4:30 PM Eastern Time, with participant dial-in numbers provided for both domestic and international callers [2]. - A live audio webcast will be available, and a replay will be accessible approximately three hours after the call until April 13, 2026 [2].

Core Insights - IMUNON, Inc. is a clinical-stage biotechnology company focused on DNA-mediated immunotherapy, currently in Phase 3 development with its lead product IMNN-001 for advanced ovarian cancer [1][5] Group 1: Financial Results and Conference Call - The company will host a conference call on March 31, 2026, at 11:00 a.m. EDT to discuss financial results for the year ended December 31, 2025, and provide updates on its clinical development program [1][2] Group 2: Clinical Development and Technology - IMNN-001 is a DNA-based immunotherapy that instructs the body to produce cancer-fighting molecules at the tumor site and has completed multiple clinical trials, including a Phase 2 trial and is currently in a Phase 3 trial [5] - The company has also completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101, and aims to advance its non-viral DNA technology through various modalities [4][5]

Core Insights - Miata Metals Corp. has announced significant drill results from its Sela Creek Gold Project, particularly from the Big Berg target, indicating a robust gold mineralization system [1][2][4] Drill Results - The drilling at Big Berg has yielded the strongest intercepts to date, with notable results including: - 67.5 m at 1.13 g/t Au from surface - 96 m at 1.41 g/t Au from 96 m - High-grade zones such as 18.1 m at 2.95 g/t Au and 7.7 m at 5.79 g/t Au [3][6] - Additional drill holes confirmed continuity of gold mineralization, with results including: - 7 m at 3.75 g/t Au from 96 m in DDH-BB-001 - 25 m at 0.90 g/t Au from 69 m in DDH-BB-002 - 7.25 m at 2.79 g/t Au from 90.75 m in DDH-BB-004 [3][4] Geological Context - Big Berg is located approximately 1 km southeast of Jons Trend, within the same structural corridor, suggesting a potential link between the two mineralized zones [2][5][15] - The mineralization at Big Berg is characterized by broad zones of gold mineralization with local high-grade intervals, indicating a robust and extensive system [5][21] Future Exploration Plans - The company is continuing drilling at Big Berg to further define the scale and continuity of mineralization, with plans to expand discovery drilling across multiple high-priority targets [18][22] - Both Big Berg and Jons Trend remain open along strike and at depth, highlighting significant potential for further exploration and resource definition [17][18]

Core Insights - Mineralys Therapeutics, Inc. has appointed Jeffrey A. Munsie as Chief Legal Officer to enhance its legal and compliance capabilities [1][2] Company Overview - Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines for hypertension and related comorbidities, including chronic kidney disease (CKD) and obstructive sleep apnea (OSA) [5] - The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [5][6] Leadership Appointment - Jeffrey A. Munsie brings nearly 25 years of legal experience in the biopharma industry, having previously served as Chief Legal Officer at Orbital Therapeutics [2][3] - Munsie's appointment is expected to be instrumental in advancing the company's growth and legal strategies [2][3] Compensation Details - Munsie received an inducement stock option award covering 90,000 shares and a restricted stock unit award covering 67,900 shares of Mineralys common stock [3][4] - The stock options will vest over a four-year period, with specific vesting schedules outlined [4] Product Development - Lorundrostat is designed to treat uncontrolled hypertension and has shown a 40-70% reduction in plasma aldosterone concentration in hypertensive participants [6][7] - The company has completed six late-stage clinical trials for lorundrostat, demonstrating its efficacy and safety profile [7]

Core Viewpoint - Bitcoin Depot has announced a leadership transition with Scott Buchanan stepping down as CEO and Alex Holmes appointed as the new CEO and Chairman of the Board, indicating a strategic shift as the company expands its fintech offerings beyond Bitcoin ATMs [1][2][3]. Leadership Transition - Scott Buchanan has resigned as CEO to pursue other opportunities, effective immediately [1]. - Alex Holmes, previously Chairman and CEO of MoneyGram International, has been appointed as the new CEO and Chairman of the Board, bringing extensive experience in global payments and fintech [2][5]. - Brandon Mintz, the founder of Bitcoin Depot, will transition to a non-executive board member role while advising Holmes, ensuring continuity in leadership [4]. Strategic Direction - The leadership change aligns with Bitcoin Depot's strategy to diversify its platform and revenue streams beyond its core Bitcoin ATM network [3]. - Holmes emphasizes priorities such as operational stability, regulatory progress, and the evolution of Bitcoin Depot into a more diversified fintech platform [6]. Company Background - Bitcoin Depot, founded in 2016, operates the largest Bitcoin ATM network in North America with over 9,000 kiosks globally as of August 2025, providing users with efficient means to convert cash into Bitcoin [7].